Burning Rock Biotech Ltd Financials
This page shows Burning Rock Biotech Ltd (BNR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Burning Rock Biotech Ltd has an operating margin of -69.3%, meaning the company retains $-69 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -124.5% the prior year.
Burning Rock Biotech Ltd's revenue declined 6.6% year-over-year, from $75.7M to $70.7M. This contraction results in a growth score of 10/100.
Burning Rock Biotech Ltd carries a low D/E ratio of 0.52, meaning only $0.52 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.92, Burning Rock Biotech Ltd holds $2.92 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 97/100.
While Burning Rock Biotech Ltd generated -$12.6M in operating cash flow, capex of $742K consumed most of it, leaving -$13.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Burning Rock Biotech Ltd passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Burning Rock Biotech Ltd generates $0.27 in operating cash flow (-$12.6M OCF vs -$47.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Burning Rock Biotech Ltd generated $70.7M in revenue in fiscal year 2024. This represents a decrease of 6.6% from the prior year.
Burning Rock Biotech Ltd's EBITDA was -$41.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 44.6% from the prior year.
Burning Rock Biotech Ltd generated -$13.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 64.0% from the prior year.
Burning Rock Biotech Ltd reported -$47.5M in net income in fiscal year 2024. This represents an increase of 48.4% from the prior year.
Burning Rock Biotech Ltd held $71.2M in cash against $0 in long-term debt as of fiscal year 2024.
Burning Rock Biotech Ltd's gross margin was 70.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 2.7 percentage points from the prior year.
Burning Rock Biotech Ltd's operating margin was -69.3% in fiscal year 2024, reflecting core business profitability. This is up 55.2 percentage points from the prior year.
Burning Rock Biotech Ltd's net profit margin was -67.2% in fiscal year 2024, showing the share of revenue converted to profit. This is up 54.4 percentage points from the prior year.
Burning Rock Biotech Ltd invested $31.8M in research and development in fiscal year 2024. This represents a decrease of 34.9% from the prior year.
Burning Rock Biotech Ltd invested $742K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 35.0% from the prior year.
BNR Income Statement
| Metric | Q4'24 | Q4'23 | Q4'22 | Q2'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A |
BNR Balance Sheet
| Metric | Q4'24 | Q4'23 | Q4'22 | Q2'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|
| Total Assets | $121.3M-17.2% | $146.5M-36.4% | $230.2M-17.2% | $277.9M-22.3% | $357.6M-12.4% | $408.1M |
| Current Assets | $106.4M-14.6% | $124.5M-31.8% | $182.5M-16.4% | $218.4M-23.6% | $285.7M-26.1% | $386.8M |
| Cash & Equivalents | $71.2M-17.8% | $86.6M-34.0% | $131.3M-23.4% | $171.5M-23.7% | $224.6M-22.7% | $290.5M |
| Inventory | $8.6M-11.7% | $9.7M-48.6% | $18.9M-2.4% | $19.4M+0.1% | $19.3M+85.5% | $10.4M |
| Accounts Receivable | $20.8M+16.6% | $17.9M+12.1% | $15.9M+5.8% | $15.1M+4.2% | $14.5M+7.0% | $13.5M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $41.7M+9.0% | $38.3M-38.5% | $62.2M-2.9% | $64.1M-5.8% | $68.0M+83.3% | $37.1M |
| Current Liabilities | $36.5M-1.6% | $37.1M-37.8% | $59.7M+11.2% | $53.7M-8.1% | $58.4M+57.8% | $37.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $0 |
| Total Equity | $79.6M-26.5% | $108.2M-35.6% | $167.9M-21.5% | $213.8M-26.2% | $289.6M-22.0% | $371.0M |
| Retained Earnings | -$575.4M-6.0% | -$542.8M-17.0% | -$463.9M-12.9% | -$410.9M-17.5% | -$349.7M-60.9% | -$217.3M |
BNR Cash Flow Statement
| Metric | Q4'24 | Q4'23 | Q4'22 | Q2'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A |
BNR Financial Ratios
| Metric | Q4'24 | Q4'23 | Q4'22 | Q2'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 2.92-0.4 | 3.36+0.3 | 3.06-1.0 | 4.07-0.8 | 4.89-5.6 | 10.45 |
| Debt-to-Equity | 0.52+0.2 | 0.35-0.0 | 0.37+0.1 | 0.30+0.1 | 0.23+0.2 | 0.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Burning Rock Biotech Ltd's annual revenue?
Burning Rock Biotech Ltd (BNR) reported $70.7M in total revenue for fiscal year 2024. This represents a -6.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Burning Rock Biotech Ltd's revenue growing?
Burning Rock Biotech Ltd (BNR) revenue declined by 6.6% year-over-year, from $75.7M to $70.7M in fiscal year 2024.
Is Burning Rock Biotech Ltd profitable?
No, Burning Rock Biotech Ltd (BNR) reported a net income of -$47.5M in fiscal year 2024, with a net profit margin of -67.2%.
What is Burning Rock Biotech Ltd's EBITDA?
Burning Rock Biotech Ltd (BNR) had EBITDA of -$41.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Burning Rock Biotech Ltd's gross margin?
Burning Rock Biotech Ltd (BNR) had a gross margin of 70.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Burning Rock Biotech Ltd's operating margin?
Burning Rock Biotech Ltd (BNR) had an operating margin of -69.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Burning Rock Biotech Ltd's net profit margin?
Burning Rock Biotech Ltd (BNR) had a net profit margin of -67.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Burning Rock Biotech Ltd's free cash flow?
Burning Rock Biotech Ltd (BNR) generated -$13.4M in free cash flow during fiscal year 2024. This represents a 64.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Burning Rock Biotech Ltd's operating cash flow?
Burning Rock Biotech Ltd (BNR) generated -$12.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Burning Rock Biotech Ltd's total assets?
Burning Rock Biotech Ltd (BNR) had $121.3M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Burning Rock Biotech Ltd's capital expenditures?
Burning Rock Biotech Ltd (BNR) invested $742K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Burning Rock Biotech Ltd spend on research and development?
Burning Rock Biotech Ltd (BNR) invested $31.8M in research and development during fiscal year 2024.
What is Burning Rock Biotech Ltd's current ratio?
Burning Rock Biotech Ltd (BNR) had a current ratio of 2.92 as of fiscal year 2024, which is generally considered healthy.
What is Burning Rock Biotech Ltd's debt-to-equity ratio?
Burning Rock Biotech Ltd (BNR) had a debt-to-equity ratio of 0.52 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Burning Rock Biotech Ltd's return on assets (ROA)?
Burning Rock Biotech Ltd (BNR) had a return on assets of -39.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Burning Rock Biotech Ltd's cash runway?
Based on fiscal year 2024 data, Burning Rock Biotech Ltd (BNR) had $71.2M in cash against an annual operating cash burn of $12.6M. This gives an estimated cash runway of approximately 68 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Burning Rock Biotech Ltd's Piotroski F-Score?
Burning Rock Biotech Ltd (BNR) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Burning Rock Biotech Ltd's earnings high quality?
Burning Rock Biotech Ltd (BNR) has an earnings quality ratio of 0.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Burning Rock Biotech Ltd?
Burning Rock Biotech Ltd (BNR) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.